

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

TITLE PAGE

Full-length title:

Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant

Short title (for the running head): qPCR for the SARS-CoV-2 Marseille-4 variant

Author list: Marielle BEDOTTO¹, Pierre-Edouard FOURNIER^{1,2}, Linda HOUHAMDI¹, Anthony LEVASSEUR^{1,2}, Jeremy DELERCE¹, Lucile PINAULT¹, Abdou PADANE³, Amanda CHAMIEH^{2,4}, Hervé TISSOT-DUPONT¹, Philippe BROUQUI^{1,2}, Cheikh SOKHNA^{5,6}, Eid AZAR⁴, Rachid SAILE⁷, Souleymane MBOUP³, Idir BITAM⁸, Philippe COLSON^{1,2}, Didier RAOULT^{1,2} *

Affiliations: ¹ IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France; ² Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille, France; ³ Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formations (IRESSEF), arrondissement 4 rue 2D1, pôle urbain de Diamniadio, Dakar, Sénégal; ⁴ Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon; ⁵ Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), Campus International IRD-UCAD de l'IRD, Dakar, Senegal; ⁶ Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean Moulin, 13005 Marseille, France; ⁷ Hassan II University of Casablanca, Morocco; ⁸ Ecole supérieure en sciences de

26 l'aliment et des industries agro-alimentaires, Alger, Algeria.

27 * **Corresponding author:** Didier RAOULT, IHU - Méditerranée Infection, 19-21 boulevard

28 Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:

29 didier.raoult@gmail.com

30

31 **Keywords (5):** SARS-CoV-2; Covid-19; variant; Marseille-4; qPCR; diagnosis; molecular

32 epidemiology

33 **Word counts:** abstract: 243; text: 1,000

34 **Figures:** 2; **Table:** 1; **References:** 11.

35

36

37

ABSTRACT

38

39 **Introduction.** The SARS-CoV-2 pandemic has been associated with the occurrence since
40 summer 2020 of several viral variants that overlapped or succeeded each other in time. Those
41 of current concern harbor mutations within the spike receptor binding domain (RBD) that may
42 be associated with viral escape to immune responses. In our geographical area a viral variant
43 we named Marseille-4 harbors a S477N substitution in this RBD.

44 **Materials and methods.** We aimed to implement an in-house one-step real-time reverse
45 transcription-PCR (qPCR) assay with a hydrolysis probe that specifically detects the SARS-
46 CoV-2 Marseille-4 variant.

47 **Results.** All 6 cDNA samples from Marseille-4 variant strains identified in our institute by
48 genome next-generation sequencing (NGS) tested positive using our Marseille-4 specific
49 qPCR, whereas all 32 cDNA samples from other variants tested negative. In addition, 39/42
50 (93%) respiratory samples identified by NGS as containing a Marseille-4 variant strain and
51 0/26 samples identified as containing non-Marseille-4 variant strains were positive. Finally,
52 1,585/2,889 patients SARS-CoV-2-diagnosed in our institute, 10/277 (3.6%) respiratory
53 samples collected in Algeria, and none of 207 respiratory samples collected in Senegal,
54 Morocco, or Lebanon tested positive using our Marseille-4 specific qPCR.

55 **Discussion.** Our in-house qPCR system was found reliable to detect specifically the
56 Marseille-4 variant and allowed estimating it is involved in more than half of our SARS-CoV-
57 2 diagnoses since December 2020. Such approach allows the real-time surveillance of SARS-
58 CoV-2 variants, which is warranted to monitor and assess their epidemiological and clinical
59 characteristics based on comprehensive sets of data.

60

61

TEXT

62

63 **1. Introduction**

64 Since the onset of the SARS-CoV-2 pandemic in December 2019 in China, almost 100
65 million cases have been reported worldwide as on January 28th, 2021
66 (<https://www.ecdc.europa.eu/en/covid-19-pandemic>). This has been associated with the
67 occurrence since summer 2020 of several viral variants that overlapped or succeeded each
68 other in time [1-3]. Those of current concern harbor mutations within the spike glycoprotein,
69 particularly within the spike receptor binding domain (RBD) that leads to viral entry into host
70 cells by binding to the ACE2 receptor (Figure 1) [4]. Such SARS-CoV-2 variants include the
71 20I/501Y.V1 [3], 20H/501Y.V2 [5], and 20J/501Y.V3 [6] strains that harbor a N501Y
72 substitution in the spike RBD and were reported in the UK and in South Africa, as highly
73 transmissible, and in Brazil, respectively. In our geographical area we detected 10 viral
74 variants since June 2020 [1]. One of them, we named Marseille-4, harbors a S477N
75 substitution in the spike RBD that has been associated with an improved binding affinity to
76 ACE2 [6] and a broad resistance to monoclonal neutralizing antibodies [7]. It predominates in
77 Marseille since August 2020, has been reported to spread in Europe since early summer and
78 was classified as the Nextstrain 20A.EU2 lineage [1, 2]. The continuous emergence of new
79 SARS-CoV-2 variants, including some of substantial concern regarding their transmissibility
80 and their possible ability to evade immune responses [8-10], warrants to set up strategies for
81 their detection and surveillance. SARS-CoV-2 incidence is currently substantial in several
82 countries including France, and in our institute we for instance diagnose >100 new cases
83 daily. Therefore, alternative strategies to sequencing are useful for variant screening. We
84 aimed to implement an in-house one-step real-time reverse transcription-PCR (qPCR) assay
85 that specifically detects the SARS-CoV-2 Marseille-4 variant.

86 **2. Material and methods**

87 SARS-CoV-2 genomes from our institute sequence database and from the GISAID
88 database (<https://www.gisaid.org/>) were used to design a primer pair and a hydrolysis probe.
89 These sequences target a fragment of the nsp4 gene that contains nucleotide position 9,526 of
90 the viral genome [in reference to genome GenBank Accession no. NC_045512.2 (Wuhan-Hu-
91 1 isolate)] where is located a hallmark mutation G>U of the SARS-CoV-2 Marseille-4
92 variant. The sequences of the qPCR primers and probe are shown in Table 1. The qPCR was
93 performed by adding 5 µL of extracted viral RNA to 15 µL of reaction mixture containing 5
94 µL of 4X TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific, Grand Island,
95 NY, USA), 0.5 µL of forward primer (10 pmol/µL), 0.5 µL of reverse primer (10 pmol/µL),
96 0.4 µL of probe (10 pmol/µL), and 8.6 µL of water. PCR conditions were as follows: reverse
97 transcription at 50°C for 10 min, then a hold at 95°C for 20 sec followed by 40 cycles
98 comprising a denaturation step at 95°C for 15 sec and a hybridization-elongation step at 60°C
99 for 60 sec. This qPCR was run on a LC480 thermocycler (Roche Diagnostics, Mannheim,
100 Germany).

101

102 **3. Results**

103 Firstly, we tested a panel of 38 cDNA samples from each of the 10 variants named
104 Marseille-1 to Marseille-10 that we identified by genome next-generation sequencing (NGS)
105 and circulated since summer 2020 in our geographical area (6 from Marseille-4 strains, 5 from
106 Marseille-5 strains, 5 from Marseille-3 strains, 4 from Marseille-1 strains, and 3 from strains
107 classified in each of the variants Marseille-2, Marseille-6, Marseille-7, Marseille-8, Marseille-
108 9, and Marseille-10) [1]. All 6 Marseille-4 samples tested positive whereas all 32 samples
109 from other variants tested negative. Secondly, we tested 42 samples identified in our institute
110 by genome NGS [1] as being from patients infected with a SARS-CoV-2 Marseille-4 variant:

111 39 of them (93%) were positive using our Marseille-4 specific qPCR. Thirdly, we tested 26
112 samples identified by next-generation genome sequencing as containing SARS-CoV-2 strains
113 that were not Marseille-4 variants (including 17 N501Y variants, 5 Marseille-2 variants, 3
114 clade 20A strains and 1 clade 20C strain): none of them were positive using our Marseille-4
115 specific qPCR. Positive and negative predictive values of Marseille-4 detection by our qPCR
116 were 100% and 90%, respectively. Finally, we tested with our Marseille-4 specific qPCR the
117 respiratory samples from 2,889 patients SARS-CoV-2-diagnosed in our institute. None of 22
118 patients' samples collected in June, 20 (5.6%) of 357 patients' samples collected in July, and
119 1,565 (53%) of 2,954 patients' samples collected in December and January tested positive
120 (Figure 2). These results are congruent with those obtained based on genome NGS that
121 showed that the Marseille-4 variant emerged in our geographical area in July and has been
122 predominant since August 2020 [1]. In addition, we found that 10 (3.6%) of 277 respiratory
123 samples collected in Algeria in September-October tested positive using our Marseille-4
124 specific qPCR, while none of 94 respiratory samples collected in Senegal in September-
125 October, of 94 samples collected in Morocco in November 2020, and of 19 samples collected
126 in Lebanon in October 2020, tested positive.

127

128 **4. Discussion**

129 Our in-house qPCR system was found reliable to detect specifically the Marseille-4
130 variant and allowed estimating it is involved in more than half of our SARS-CoV-2 diagnoses
131 since December 2020. This assay is currently routinely used in our clinical microbiology and
132 virology laboratory to screen systematically all samples found SARS-CoV-2-positive using
133 the first-line qPCR diagnosis assay, which allows the real-time classification of viral strains in
134 more than half of the diagnoses (Figure 2). In case of negativity of this Marseille-4 specific
135 qPCR, samples are tested using alternative qPCR assays that are specific to other variants that

136 circulate at a lower incidence level than the Marseille-4 variant, or they are submitted to next-
137 generation sequencing in case of cycle threshold value (Ct) <18 with the SARS-CoV-2 qPCR
138 diagnosis test [1, 11]. Such approach based on qPCR assays targeting specifically SARS-
139 CoV-2 variants allows their real-time surveillance, which is warranted to monitor and assess
140 their epidemiological and clinical characteristics based on comprehensive sets of data. In
141 addition, in-house qPCR assays can be implemented rapidly, easily and at low cost on various
142 open qPCR microplate platforms, which may allow adapting continuously the diagnosis
143 strategies to the emergence and dynamics of SARS-CoV-2 variants.

144

145

146 **Credit authorship contribution statement**

147 Conceived and designed the experiments: DR, PC. Contributed materials/analysis tools: MB,
148 PEF, LH, AL, JD, LP, AP, AC, HTD, PB, CS, EA, RS, SM, IB, PC. Analyzed the data: MB,
149 PC, PEF, DR. Wrote the paper: PC, MB, DR.

150

151 **Funding**

152 This work was supported by the French Government under the “Investments for the Future”
153 program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-
154 IAHU-03 and was also supported by Région Provence Alpes Côte d’Azur and European
155 funding FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de
156 Recherche et d’Innovation Mutualisées Méditerranée Infection), FEDER PA 0000320
157 PRIMMI.

158

159 **Declaration of Competing Interest**

160 The authors have no conflicts of interest to declare. Funding sources had no role in the design

161 and conduct of the study; collection, management, analysis, and interpretation of the data; and
162 preparation, review, or approval of the manuscript.

163

164 **Ethics**

165 This study has been approved by the ethics committee of the University Hospital Institute
166 Méditerranée Infection, Marseille, France, with the registration number 2020-029.

167

168 **Acknowledgments**

169 This manuscript text has been edited by a native English speaker.

170

171 **References**

- 172 [1] P.E. Fournier, P. Colson, A. Levasseur, et al. Emergence and outcome of the SARS-
173 CoV-2 “Marseille-4” variant. IHU Pre-prints (2021) doi: <https://doi.org/10.35081/xcrm-6t77>.
174
- 175 [2] E.B. Hodcroft, M. Zuber, S. Nadeau, et al. Emergence and spread of a SARS-CoV-2
176 variant through Europe in the summer of 2020, medRxiv (2020) doi:
177 <https://doi.org/10.1101/2020.10.25.20219063>.
- 178 [3] K. Leung, M.H. Shum, G.M. Leung, T.T. Lam, J.T. Wu. Early transmissibility
179 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom,
180 October to November 2020, Euro. Surveill. 26 (2021) 2002106.
- 181 [4] A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Velesler. Structure,
182 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell 181 (2020)
183 281-92.
- 184 [5] H. Tegally, E. Wilkinson, M. Giovanetti, et al. Emergence and rapid spread of a new
185 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with
186 multiple spike mutations in South Africa. medRxiv (2020) 12.21.20248640; doi:
187 <https://doi.org/10.1101/2020.12.21.20248640>
- 188 [6] M. Mejdani, K. Haddadi, C. Pham, R. Mahadevan. SARS-CoV-2 receptor binding
189 mutations and antibody-mediated immunity. bioRxiv (2021) doi:
190 <https://doi.org/10.1101/2021.01.25.427846>.
- 191 [7] Z. Liu, L.A. VanBlargan, L.M. Bloyet, et al. Landscape analysis of escape variants
192 identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody
193 neutralization. bioRxiv (2020) doi: <https://doi.org/10.1101/2020.11.06.372037>.

- 194 [8] D. Harrington, B. Kele, S. Pereira, et al. Confirmed Reinfection with SARS-CoV-2
195 Variant VOC-202012/01. *Clin. Infect Dis* (2021) ciab014. doi: 10.1093/cid/ciab014.
196 Online ahead of print.
- 197 [9] P. Colson, M. Finaud, N. Levy, J.C. Lagier, D. Raoult. Evidence of SARS-CoV-2 re-
198 infection with a different genotype, *J Infect* (2020) S0163-4453(20)30706-4. doi:
199 10.1016/j.jinf.2020.11.011. Online ahead of print.
- 200 [10] J.I. Cohen, P.D. Burbelo. Reinfection with SARS-CoV-2: Implications for Vaccines,
201 *Clin. Infect. Dis.* (2020) ciaa1866. doi: 10.1093/cid/ciaa1866. Online ahead of print.
- 202 [11] G. Haddad, S. Bellali, A. Fontanini, et al. Rapid Scanning Electron Microscopy
203 Detection and Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2 and
204 Other Respiratory Viruses. *Front. Microbiol.* 11 (2020) 596180.
205
206
207

208

TABLE

209

210 **Table 1. Primers and probe of the Marseille-4 variant-specific qPCR**

211

Name	Sequence (5'-3')	Positions *
<i>Primers:</i>		
Pri_IHU_C4_5_MBF	GAGGTTTAGAAGAGCTTTTGGTGA	9,460-9,483
Pri_IHU_C4_5_MBR	CCAGGTAAGAATGAGTAAACTGGTG	9,549-9,573
<i>Probe (6FAM-labelled):</i>		
Pro_IHU_C4_5_MBP	CCTTAT <u>TTC</u> ATTCACTGTACTCTG	9,520-9,543

212

213 * in reference to SARS-CoV-2 genome GenBank Accession no. NC_045512.2 (Wuhan-Hu-1

214 isolate). The nucleotide carrying the mutation specific to the Marseille-4 variant is covered

215 by the probe and underlined.

216

217

Fig. 1




Fig. 2

